Skip to main content
Clinical Trials/NCT01652404
NCT01652404
Unknown
Phase 3

PROcalcitonin to SHORTen Antibiotics Duration in PEDiatricICU Patients (ProShort-Ped) Trial

Hunan Children's Hospital1 site in 1 country600 target enrollmentMarch 2011
ConditionsSepsis

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Sepsis
Sponsor
Hunan Children's Hospital
Enrollment
600
Locations
1
Primary Endpoint
Average antibiotics duration
Last Updated
13 years ago

Overview

Brief Summary

The purpose of this study is to give conclusive evidence on whether serial PCT (Procalcitonin) measurements can facilitate individual decision-making and shorten antibiotic treatment duration in patients with sepsis in the pediatric ICU (Intensive Care Unit).

Detailed Description

In this study, the investigators aimed to design a multi-center trial addressing aforementioned flaws. The investigators will set stricter inclusion criteria, collect complete data on relapse or secondary infection, and include sufficient number of patients to show non-inferiority to conventional therapy by a delta margin of 10% \[11\]. The investigators aimed to give conclusive evidence on whether serial PCT measurements can facilitate individual decision-making and shorten antibiotic treatment duration in patients with sepsis in the pediatric ICU.

Registry
clinicaltrials.gov
Start Date
March 2011
End Date
December 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All patients with laboratory- or image-confirmed severe infection at admission or during stay in pediatric ICU will be eligible for inclusion.
  • \* Definition of laboratory- or image-confirmed severe infection:
  • Two or more of four signs of inflammation:
  • Temperature \>38.3℃ or \<36℃
  • Heart rate \> 90 beats/min
  • Respiratory rate \>20 breaths/min or PaCO2 (Arterial pressure of carbon dioxide) \< 32 mmHg
  • WBC (White Blood Cell count) \> 12,000 cells/mm3, \<4000 cells/mm3, or \>5% band-form WBC
  • Initial Procalcitonin \> 0.5 ng/mL
  • Presence of either laboratory or image evidence of infection
  • Laboratory evidence: Sign of inflammation in urine, CSF (Cerebrospinal Fluid), ascites, pleural effusion or local abscess

Exclusion Criteria

  • Age greater than 15 years or less than 1 month
  • Known pregnancy
  • Expected ICU stay less than 3 days
  • Neutropenia: ANC (Absolute Neutrophil Count) \<500/mm3
  • Specific infections for which long-term antibiotic treatment is strongly recommended:
  • Lobar pneumonia or empyema
  • Bacterial meningitis
  • Osteomyelitis
  • Infective endocarditis
  • Local abscess

Outcomes

Primary Outcomes

Average antibiotics duration

Time Frame: 28 days

Efficacy endpoint

28-day mortality rate

Time Frame: 28 days

Safety endpoint

Secondary Outcomes

  • Proportion of antibiotics use in both arms(28 days)
  • Length of ICU stay(90 days)
  • Recurrence of fever within 72 hours of antibiotics discontinuation(28 days)
  • SOFA score (Sequential Organ Failure Assessment score)(28 days)
  • Reinfection rate between 72-hours and 28 days post antibiotics discontinuation(28 days)
  • 90-day all-cause mortality(90 days)
  • 90-day readmission rate(90 days)

Study Sites (1)

Loading locations...

Similar Trials